We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Antibodies That Block Metalloproteinase Activity Prevent Crohn’s Disease

By LabMedica International staff writers
Posted on 03 Jan 2012
A new approach to treating chronic autoimmune diseases such as Crohn’s disease and rheumatoid arthritis is based on monoclonal antibodies that specifically target the catalytic zinc-protein complex that is the functional heart of proteolytic enzymes known as metalloproteinases.

Metalloproteinases 2 and 9 are members of the group of enzymes known as matrix metalloproteinases (MMPs). More...
Collectively they are capable of degrading most kinds of extracellular matrix proteins. They are known to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands (such as the FAS ligand), and chemokine activation or inactivation. MMPs are also thought to play a major role in cellular activities such as proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis, and host defense. The MMPs are inhibited by specific endogenous tissue inhibitor of metalloproteinases (TIMPs), which comprise a family of four protease inhibitors: TIMP1, TIMP2, TIMP3, and TIMP4.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) used an innovative immunization strategy that exploited aspects of molecular mimicry to produce inhibitory antibodies that showed TIMP-like binding mechanisms toward the activated forms of matrix metalloproteinases 2 and 9 (gelatinases).

In a paper published in the December 25, 2011, online edition of the journal Nature Medicine the investigators described how they immunized mice with a synthetic molecule that mimicked the conserved structure of the metalloenzyme catalytic zinc-histidine complex residing within the enzyme active site. This immunization procedure yielded selective function-blocking monoclonal antibodies directed against the catalytic zinc-protein complex and enzyme surface conformational epitopes of endogenous gelatinases.

In an in vivo study, treatment of a mice model of Crohn’s disease with the monoclonal antibodies prevented development of the syndrome. The action of the antibodies was more specific than that of synthetic low molecular inhibitors of MMPs and had fewer undesirable side effects.

“We are excited not only by the potential of this method to treat Crohn’s, but by the potential of using this approach to explore novel treatments for many other diseases,” said senior author Dr. Irit Sagi, professor of biological regulation at the Weizmann Institute of Science.

Related Links:
Weizmann Institute of Science



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.